Catalyst Capital Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 10.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 3,515 shares of the biopharmaceutical company’s stock after selling 404 shares during the period. Catalyst Capital Advisors LLC’s holdings in Gilead Sciences were worth $209,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Qube Research & Technologies Ltd grew its holdings in Gilead Sciences by 1,482.2% during the fourth quarter. Qube Research & Technologies Ltd now owns 812,742 shares of the biopharmaceutical company’s stock valued at $59,013,000 after purchasing an additional 761,375 shares during the last quarter. Congress Wealth Management LLC DE bought a new position in Gilead Sciences in the 4th quarter worth $419,000. Mercer Global Advisors Inc. ADV raised its holdings in Gilead Sciences by 11.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 72,464 shares of the biopharmaceutical company’s stock worth $5,262,000 after acquiring an additional 7,216 shares during the period. Envestnet Asset Management Inc. lifted its position in Gilead Sciences by 3.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 2,028,952 shares of the biopharmaceutical company’s stock worth $147,322,000 after acquiring an additional 73,714 shares during the last quarter. Finally, Sweet Financial Partners LLC bought a new stake in Gilead Sciences during the fourth quarter valued at about $225,000. Institutional investors own 80.16% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on GILD. StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. BMO Capital Markets began coverage on Gilead Sciences in a research report on Tuesday, June 7th. They issued a “hold” rating and a $63.00 price target on the stock. Morgan Stanley increased their price objective on Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a research report on Friday, July 15th. SVB Leerink assumed coverage on shares of Gilead Sciences in a research report on Monday, May 23rd. They set a “market perform” rating and a $68.00 target price on the stock. Finally, TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $72.40.
Gilead Sciences Price Performance
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 89.02%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Why Apple is Primed to Take a Bite Out of Live Sports
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.